Aveanna Healthcare (AVAH) Stock Forecast and Price Target (2026)

The average target of $15.05 sits above the $13.12 price, +14.7%. The median is $15.00, and where the two differ the median is the steadier read, because one unusually high or low target cannot drag it.

The published targets span $13.00 to $16.00. That gap is 20% of the average target, which counts as narrow disagreement. A spread that tight means the analysts broadly agree on the model, so the consensus is a reasonably stable read of a shared view.

The useful move is to read the high target as one bull scenario and the low target as one bear scenario, then ask which set of assumptions you find more plausible. Both cases are worked through on the AVAH is it a buy page.

In the last six months there have been 10 raises and 1 cut among these actions. The direction of revisions is often more telling than the level, because it shows which way informed opinion is moving.

Of the analysts with a published rating, 8 say buy, 3 say hold, and 0 say sell, so 73% carry a buy. That mix has been broadly steady over the last three months.

The distribution says more than the label. Sell ratings are rare across the entire market for structural reasons, so a stock with no sell ratings is unremarkable, while even a handful of them is worth understanding.

• It is a 12-month model output. An analyst picks assumptions for revenue, margin, and a multiple, and the target falls out of the arithmetic. Change one assumption and the target moves a lot.
• The distribution is skewed. Sell-side coverage carries far more buy ratings than sell ratings across the whole market, so the average is not a balanced vote.
• Targets follow price as often as they lead it. Revisions frequently arrive after a move, not before, which is why a rising target is weak evidence on its own.
• Nobody is scored on it. There is no cost to a target that never gets close, so treat accuracy as unverified unless you check the firm's record yourself.

For the fiscal year ending Dec 2026, the 11 analysts publishing estimates on AVAH expect earnings of $0.82 per share (+37% on the year before) and revenue of $2.7 billion (+11%).

Estimates are the most widely published forecast there is: many more analysts model a company's earnings than publish a price target on it. They are also revised constantly, and the direction of those revisions into a report is often more informative than the level. Aveanna Healthcare next reports on November 12, 2026, which is when these figures get tested against actual results.

Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering AVAH do not put out a 2030 number. Anything presenting one is extrapolating a growth rate of its own, and a figure produced that way tells you about the assumption chosen, not about the company.

The furthest-out consensus that exists is for the fiscal year ending Dec 2027: analysts expect earnings of $0.91 per share, +10% on the fiscal year ending Dec 2026 estimate of $0.82. Beyond that, nobody publishes estimates, so any later number is an extrapolation.

On the figures we hold as of November 2026, AVAH trades at about 10.4 times trailing earnings and 14.5 times forward earnings. A forward multiple at or above the trailing one means the market is not pricing in earnings growth over the next year. Keep that in mind before assuming a long-horizon rise.

For a ten-year question, that frame is more useful. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Aveanna Healthcare can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.

In short: the drivers cited most often are State Medicaid rate increases versus caregiver wages, Preferred payer agreements and government affairs, Consolidating a fragmented pediatric nursing market. The risk cited most often against it is payer concentration is the dominant risk: with ~81% of revenue tied to Medicaid and Medicaid managed care, a single adverse state budget or rate freeze reaches the income statement directly, and the Medicaid funding changes in the 2025 federal tax law leave states with less room to be generous.

Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the AVAH is it a buy page.